TMS denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for tms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies TMS as Duplicate Therapy — and How to Appeal

Transcranial magnetic stimulation (TMS) is a non-invasive brain-stimulation treatment most commonly used for major depressive disorder and certain other conditions. Aetna sometimes denies TMS as "duplicate therapy" when you are concurrently receiving another treatment — typically antidepressant medication or psychotherapy — that Aetna categorizes as serving the same therapeutic purpose. This denial reason is frequently incorrect: TMS and pharmacotherapy act through distinct mechanisms and are routinely combined in clinical practice when monotherapy has been inadequate.

## Why This Denial Is Appealable

A duplicate-therapy denial requires Aetna to show that the two treatments are therapeutically interchangeable for your specific case. Your clinician can directly rebut that premise by documenting: (a) the separate mechanism of action and distinct clinical role of TMS compared to your current treatment, (b) that your current treatment has not achieved adequate response, and (c) that combination is the standard of care endorsed by the relevant specialty guideline organization (e.g., the applicable American Psychiatric Association guideline). This rebuttal, grounded in your chart, is the core of a successful appeal.

## Federal Appeal Framework

• Internal appeal (Level 1): Submit within 180 days of the denial date. Aetna must decide within 30 days for pre-service and 60 days for post-service.
• External review (ACA §2719 / ERISA §503): After an adverse internal determination, you have approximately four months to request independent external review. An external reviewer — not affiliated with Aetna — evaluates whether the duplicate-therapy classification is clinically supported.
• Expedited review: If waiting would seriously jeopardize your health or ability to function, request expedited external review; Aetna must respond within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation: Current psychiatric or treating provider records confirming diagnosis, symptom severity, and functional impairment. 2. Current treatment history: Records of all ongoing treatments, with dates started and documented response (or lack thereof). 3. Mechanism distinction letter: A letter from your prescribing or treating clinician explaining that TMS acts through a different biological mechanism than your current treatment and serves a distinct clinical purpose. 4. Inadequate-response documentation: Chart notes, validated symptom scales, and clinical assessments documenting that existing treatments have not produced adequate improvement. 5. Guideline reference: Ask your clinician to note that the applicable specialty guidelines recognize combination use in treatment-resistant cases — by naming the guideline organization, not quoting specific numbers.

## Criteria-Mapping Structure

Obtain Aetna's published Clinical Policy Bulletin for TMS from Aetna.com. For each coverage criterion, build a table: (1) Aetna Policy Requirement, (2) Your Chart Evidence, (3) Document/Date. The duplicate-therapy denial specifically should be addressed with a column entry showing that the mechanisms are distinct and that combination use is clinically supported — making it impossible for a reviewer to sustain the duplicate characterization.